Loratadine 10mg Allergy Relief Film-Coated Tablets
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Loratadine 10mg Allergy Relief Film-Coated Tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains Loratadine 10mg.
For excipients see 6.1
3. PHARMACEUTICAL FORM
Film-coated tablet
Film-coated white round biconvex tablets scored on one side and marked “LR 10” on the other side.
4. CLINICAL PARTICULARS
4.1. Therapeutic indications
Loratadine tablets are indicated in the treatment of seasonal and perennial rhinitis for the relief of nasal symptoms such as sneezing, itching and discharge; and ocular symptoms such as itching and burning.
Loratadine tablets are also indicated for the relief of itching, reddening and wealing of the skin - symptoms associated with idiopathic chronic urticaria.
4.2 Posology and method of administration
Adults and children over 12 years of age:
10mg once daily (one film-coated tablet once daily). The film-coated tablet may be taken without regard to mealtime.
Children 2 to 12 years of age are dosed by weight:
Body weight more than 30 kg: 10 mg once daily (one film-coated tablet once daily).
The 10 mg film-coated tablet is not appropriate in children with a body weight less than 30 kg.
Efficacy and safety of Loratadine tablets in children under 2 years of age has not been established.
Patients with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of loratadine. An initial dose of 10 mg every other day is recommended for adults and children weighing more than 30 kg. No dosage adjustments are required in the elderly or in patients with renal insufficiency.
Loratadine tablets are for oral use.
4.3. Contraindications
Loratadine tablets are contraindicated for patients with known hypersensitivity or idiosyncrasy to Loratadine or any of the excipients in the tablets.
4.4 Special warnings and precautions for use
Loratadine should be administered with caution in patients with severe liver impairment (see section 4.2).
Caution is required with concomitant use of drugs which affect hepatic cytochromes P450 3A4 and 2D6. (see section 4.5; interaction with other medicinal products and other forms of interaction).
The administration of Loratadine should be discontinued at least 48 hours before skin tests since antihistamines may prevent or reduce otherwise positive reactions to dermal reactivity index.
Loratadine may cause dry mouth in certain patients. Therefore during long-term treatment, good oral hygiene is important for these patients, because dry mouth may increase the risk of caries.
This medicinal product contains lactose; thus patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
When administered concomitantly with alcohol, loratadine has no potentiating effects as measured by psychomotor performance studies.
Potential interaction may occur with all known inhibitors of CYP3A4 or CYP2D6 resulting in elevated levels of loratadine (see Section 5.2), which may cause an increase in adverse events.
Loratadine is metabolised in the liver by CYP2D6, but also and most preferentially by CYP3A4.
Cimetidine inhibits both of these cytochromes; erythromycin and ketoconazole both inhibit CYP3A4, whilst amfebutamone/ bupropion inhibits CYP2D6.
When these drugs are given concomitantly with Loratadine increased plasma levels of loratadine are seen but these have not been associated with adverse effects or changes to electrocardiogram. Patients may need to be initiated at a lower dose if taking amfebutamone/ bupropion concomitantly.
Quinidine, fluconazole and fluoxetine are also known to inhibit these cytochromes.
4.6 Fertility, pregnancy and lactation
There are insufficient data on the use of loratadine during pregnancy in humans to assess its possible harmfulness. Animal studies do not indicate a teratogenic risk, but reduced viability and prolonged parturition were observed in rats (See section 5.3; Preclinical safety data). The use of loratadine during pregnancy is therefore not recommended.
Loratadine is excreted in breast milk, therefore the use of loratadine is not recommended in breast-feeding women.
4.7 Effects on ability to drive and use machines
In clinical trials that assessed driving ability, no impairment occurred in patients receiving loratadine. However, patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines.
4.8 Undesirable effects
In clinical trials in a paediatric population, children aged 2 through 12 years, common adverse reactions reported in excess of placebo were headache (2.7%), nervousness (2.3%), and fatigue (1%).
In clinical trials involving adults and adolescents in a range of indications including AR and CIU, at the recommended dose of 10 mg daily, adverse reactions with loratadine were reported in 2 % of patients in excess of those treated with placebo. The most frequent adverse reactions reported in excess of placebo were somnolence (1.2%), headache (0.6%), increased appetite (0.5%) and insomnia (0.1%). Other adverse reactions reported very rarely during the post-marketing period are listed in the following table.
Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very
common (>1/l0), common (>1/100 and <1/10), uncommon (>1/1000 and <1/100), rare (> 1/10,000 and <1/1000) and very rare (<1/10,000).
|
Common |
Uncommon |
Very Rare | |
|
(> 1/100 to <1/10) |
(> 1/1,000 to |
(< 1/10,000) |
|
<1/100) | |||
|
Immune system disorders |
Anaphylaxis | ||
|
Metabolism and nutrition disorders |
Increased appetite | ||
|
Nervous system disorders |
Headache, somnolence, nervousness |
Insomnia |
Dizziness |
|
Cardiac disorders |
Tachycardia, palpitation. Isolated reports of supraventricular tachyarrythmia have been observed. Cardiac undesirable effects like prolongation of the QT interval in an electrocardiogram and arrhythmia like Torsades de Pointes may occur. | ||
|
Respiratory, thoracic and mediastinal disorders |
Pharyngitis | ||
|
Gastrointestinal disorders |
Nausea, gastritis, dyspepsia, dry mouth and nose bleeding. | ||
|
Hepatobiliary disorders |
Abnormal hepatic functions | ||
|
Skin and subcutaneous tissue disorders |
Rash, alopecia | ||
|
General disorders and administration site conditions |
Fatigue |
4.9 Overdose
Overdose with loratadine increases the occurrence of anticholinergic symptoms. Somnolence, tachycardia, and headache have been reported with overdoses.
Treatment should be started as soon as possible after the overdose. In the event of overdose, general symptomatic and supportive measures are to be instituted and maintained for as long as necessary. Administration of activated charcoal as a slurry with water may be attempted. Gastric lavage may be considered for patients with impaired consciousness, or when vomiting is contraindicated. Otherwise the stomach should be emptied (Ipecacuanha is advised) even if emesis has already occurred. Loratadine is not removed by haemodialysis and it is not known if loratadine is removed by peritoneal dialysis. Medical monitoring of the patient is to be continued after emergency treatment.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: antihistamines for systemic use.
ATC code: RO6A X13
Loratadine is an antihistamine with a tricyclic structure and has a selective and antagonistic activity on peripheric H1-receptors. It is long acting and rapidly effective with no sedative or anticholinergic activity in the majority of the population and when used at the recommended dosage.
In CNS-activity studies loratadine 10 mg did not show depressive or acute anticholinergic activity.
Loratadine does not readily cross the blood brain barrier and shows a very low affinity for brain receptors.
During prolonged treatment no clinically relevant changes were observed in vital functions, laboratory parameters, physical examination or electrocardiograms. In studies with dosages of loratadine tablets 2 to 4 times higher than the recommended dose of 10 mg, a dose-related increase in the incidence of somnolence was observed.
Loratadine has no significant affinity for histamine H2-receptors, does not inhibit the absorption of norepinephrine and exhibits hardly any effect on the cardiovascular function in intrinsic cardiac pacemaker activity. In a study in which loratadine tablets were administered at four times the clinical dosage during a period of 90 days no clinically significant increase in QTc-interval was seen on ECGs.
5.2 Pharmacokinetic properties
After oral administration, loratadine is rapidly and well absorbed and undergoes an extensive first pass metabolism, mainly by CYP3A4 and CYP2D6. The major metabolite-desloratadine (DL)- is pharmacologically active and responsible for a large part of the clinical effect. Loratadine and DL achieve maximum plasma concentrations (Tmax) between 1-1.5 hours and 1.5-3.7 hours after administration, respectively.
Increase in plasma concentrations of loratadine has been reported after concomitant use with ketoconazole, erythromycin, and cimetidine in controlled trials, but without clinically significant changes (including electrocardiographic).
Loratadine is highly bound (97 % to 99 %) and its active metabolite moderately bound (73 % to 76 %) to plasma proteins.
In healthy subjects, plasma distribution half-lives of loratadine and its active metabolite are approximately 1 and 2 hours, respectively. The mean elimination half-lives in healthy adult subjects were 8.4 hours (range = 3 to 20 hours) for loratadine and 28 hours (range = 8.8 to 92 hours) for the major active metabolite.
Approximately 40 % of the dose is excreted in the urine and 42 % in the faeces over a 10 day period and mainly in the form of conjugated metabolites. Approximately 27 % of the dose is eliminated in the urine during the first 24 hours. Less than 1 % of the active substance is excreted unchanged in active form, as loratadine or DL.
The bioavailability parameters of loratadine and of the active metabolite are dose proportional.
The pharmacokinetic profile of loratadine and its metabolites is comparable in healthy adult volunteers and in healthy geriatric volunteers.
Concomitant ingestion of food can delay slightly the absorption of loratadine but without influencing the clinical effect.
In patients with chronic renal impairment, both the AUC and peak plasma levels (Cmax) increased for loratadine and its metabolite as compared to the AUCs and peak plasma levels (Cmax) of patients with normal renal function. The mean elimination half-lives of loratadine and its metabolite were not significantly different from that observed in normal subjects. Haemodialysis does not have an effect on the pharmacokinetics of loratadine or its active metabolite in subjects with chronic renal impairment.
In patients with chronic alcoholic liver disease, the AUC and peak plasma levels (Cmax) of loratadine were double while the pharmacokinetic profile of the active metabolite was not significantly changed from that in patients with normal liver function. The elimination half-lives for loratadine and its metabolite were 24 hours and 37 hours, respectively, and increased with increasing severity of liver disease.
Loratadine and its active metabolite are excreted in the breast milk of lactating women.
5.3 Preclinical safety data
Preclinical data with loratadine reveal no special hazard for humans based on conventional studies of safety, pharmacology, repeated dose toxicity, genotoxicity, teratogenicity and carcinogenicity.
In reproductive toxicity studies, no teratogenic effects were observed. However, prolonged parturition and reduced viability of offspring were observed in rats at plasma levels (AUC) 10 times higher than those achieved with clinical doses.
Chronic toxicity studies in rats (between 2 - 240 mg/kg/day for up to 12 months) and monkeys (between 0.4 - 90 mg/kg/day for up to 17 months) demonstrated some anticholinergic effects and dose-related reversible phospholipidosis.
The clinical relevance of the findings of phospholipidosis is uncertain.
6. PHARMACEUTICAL PARTICULARS
6.1. List of excipients
Tablet core Lactose monohydrate Microcrystalline cellulose Maize starch Pregelatinized starch Hydrated colloidal silica Magnesium stearate
Film coat Hypromellose Macrogol 400 and 6000
Polishing agents Carnauba wax Talc
6.2. Incompatibilities
None known.
6.3. Shelf life
3 years.
6.4. Special precautions for storage
Store in the original package.
6.5. Nature and contents of container
PVC/Aluminium blister packs of 7 tablets.
6.6. Instructions for use and handling
None.
7 MARKETING AUTHORISATION HOLDER
Generics [UK] Ltd T/A Mylan Station Close Potters Bar Hertfordshire EN6 1TL United Kingdom
8. MARKETING AUTHORISATION NUMBER
PL 04569/0601
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
05/04/2011
10 DATE OF REVISION OF THE TEXT
02/12/2013